why choose us

First received: April 19, 2023

Clinical Trial: HepB mAb19 in Individuals With Chronic Hepatitis B Infection

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hepatitis b Virus

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Placebo-controlled, Dose-escalation Study of the Safety, Pharmacokinetics, and Antiviral Activity of a Potent Neutralizing Monoclonal Antibody in Individuals With Chronic Hepatitis B Infect

Brief Summary: This is a first-in-human, placebo-controlled, single dose, dose-escalation phase 1 study to evaluate the safety, pharmacokinetics and antiviral activity of a highly potent neutralizing anti-HBV monoclonal antibody (mAb), HepB mAb19, which targets the S-protein in individuals with chronic hepatitis B (CHB) on nucleos(t)ide analog therapy (NRTI).

Read more